Home/Filings/4/0000950170-24-132936
4//SEC Filing

Patel Samir Rashmikant 4

Accession 0000950170-24-132936

CIK 0001541157other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 5:50 PM ET

Size

10.8 KB

Accession

0000950170-24-132936

Insider Transaction Report

Form 4
Period: 2024-11-30
Transactions
  • Award

    Ordinary Shares, par value $0.0001 per share

    2024-12-02$0.00/sh+419,286,000$503,1435,235,403,500 total(indirect: By LLC)
  • Award

    Stock Option (Right to Buy)

    2024-11-30+162,604,000162,604,000 total
    Exercise: $0.00From: 2024-11-30Exp: 2034-11-30Ordinary Shares, par value $0.0001 per share (162,604,000 underlying)
  • Award

    Warrants (Right to Buy)

    2024-12-02$0.00/sh+419,286,000$503,143419,286,000 total(indirect: By LLC)
    Exercise: $0.00From: 2024-12-02Exp: 2027-12-02Ordinary Shares, par value $0.0001 per share (419,286,000 underlying)
Holdings
  • Ordinary Shares, par value $0.0001 per share

    91,396,000
Footnotes (4)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
  • [F2]On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant.
  • [F3]The stock options have an exercise price of $0.000615 per Ordinary Share.
  • [F4]The warrants have an exercise price of $0.001130 per Ordinary Share.

Documents

1 file

Issuer

Akari Therapeutics Plc

CIK 0001541157

Entity typeother

Related Parties

1
  • filerCIK 0001702447

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 5:50 PM ET
Size
10.8 KB